SW
AGN

SlateStone Wealth’s Allergan plc AGN Stock Holding History

SlateStone Wealth’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,715
Closed -$289K – 228
2019
Q3 		$289K Sell
1,715
-150
-8% -$24.4K 0.08% 138
2019
Q2 		$312K Sell
1,865
-294
-14% -$40.7K 0.09% 141
2019
Q1 		$316K Buy
+2,159
New +$313K 0.1% 129

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LP
Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SlateStone Wealth's AGN Position: Q4 2019 in Review

SlateStone Wealth sold out of Allergan plc (AGN) in Q4 2019, closing a stake of 1,715 shares — an estimated $289K sold.

SlateStone Wealth first reported a position in AGN in Q1 2019 and held it in 3 quarters. The position peaked at $316K in Q1 2019. 957 funds tracked by Wall St. Rank hold AGN as of Q4 2019.

  • SlateStone Wealth reported no remaining Allergan plc position as of Q4 2019 after selling out during the quarter.
  • SlateStone Wealth sold 1,715 Allergan plc shares in Q4 2019, an estimated $289K.
  • SlateStone Wealth first reported a position in Allergan plc in Q1 2019 and held it in 3 quarters.
  • SlateStone Wealth's Allergan plc position peaked at $316K in Q1 2019.
  • 957 funds tracked by Wall St. Rank held Allergan plc as of Q4 2019.

Based on SlateStone Wealth's 13F filing for Q4 2019, filed 6 Feb 2020.